Thus, the integration of an anti-PD-1 antibody into chemotherapeutic regimens for NPC patients and into protocols with adoptive NK-cell transfer may offer a novel and effective means of improving treatment strategies in NPC. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.